Comparing GLP-1 Receptor Agonists with SGLT2 Inhibitors for Type 2 Diabetes

April 13, 2020
Kenny Walter

Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.

Investigators from Saint Louis University discuss a new comparison of 2 drug classes that could reduce the risk of adverse cardiovascular events.

Both glucagon-like peptide-1 receptor agonists (GLP-1 RA), as well as sodium-glucose co-transport 2 inhibitors (SGLT2i) have proven cardiovascular benefits in treating patients with type 2 diabetes.

However, selecting the right drug for the right treatment can be difficult.

In a study planned to be presented at the ENDO 2020, Ali Al-Khazaali, MD, Albert Stewart, MD, and Alexis McKee, of Saint Louis University, evaluated the data to aid in the prescribing decision with regard to severity of illness and risk of adverse events for patients with type 2 diabetes mellitus.

In a HCPLive® DocTalk interview, the trio of investigators discussed their study and explained what needs to happen in the future to improve patient care and reduce the risk of cardiovascular events.